C12N 2710/10343
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2710/10343 (Viral genome or elements thereof as genetic vector) appears on 1,473 US grants and 2,489 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,473
- Published applications
- 2,489
- Assignees
- 853
- Inventors
- 3,568
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 8 | 0 |
| 1997 | 13 | 0 |
| 1998 | 33 | 0 |
| 1999 | 49 | 0 |
| 2000 | 50 | 0 |
| 2001 | 54 | 21 |
| 2002 | 67 | 144 |
| 2003 | 62 | 170 |
| 2004 | 54 | 137 |
| 2005 | 42 | 131 |
| 2006 | 64 | 120 |
| 2007 | 55 | 108 |
| 2008 | 38 | 87 |
| 2009 | 47 | 97 |
| 2010 | 45 | 96 |
| 2011 | 40 | 88 |
| 2012 | 49 | 67 |
| 2013 | 39 | 44 |
| 2014 | 38 | 62 |
| 2015 | 41 | 59 |
| 2016 | 42 | 62 |
| 2017 | 44 | 67 |
| 2018 | 47 | 81 |
| 2019 | 53 | 103 |
| 2020 | 55 | 109 |
| 2021 | 55 | 127 |
| 2022 | 64 | 135 |
| 2023 | 70 | 122 |
| 2024 | 55 | 107 |
| 2025 | 62 | 96 |
| 2026 | 37 | 49 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis in humans, and compositions comprising the same25 Aug 2026US 12,714,755 B2Pacira Therapeutics, Inc.
- Rescue of recombinant adenoviruses by CRISPR/Cas-mediated in vivo terminal resolution25 Aug 2026US 12,716,064 B2Albert-Ludwigs-Universität Freiburg
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Hiv immunogenic polypeptides and vaccines and uses thereof24 Sep 2026US 2026/0284175 A1Gilead Sciences, Inc.
- A viral vector and a vaccine composition comprising the vector24 Sep 2026US 2026/0284181 A1Rokote Laboratories Finland Oy
- Methods and compositions for cancer treatment using recombinant polypeptides24 Sep 2026US 2026/0284226 A1Infinitopes Limited
- Methods for assessing resistance to non-integrating virus vectors27 Aug 2026US 2026/0250708 A1Université De Namur
Most cited
By later US patents
- Vectors and methods for immunization or therapeutic protocols285US 6,339,068 B12002
- Adenovirus vectors for gene therapy278US 5,585,362 AThe Regents of the University of Michigan · 1996
- Packaging systems for human recombinant adenovirus to be used in gene therapy267US 5,994,128 AIntrogene B.V. · 1999
- Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus184US 5,994,106 AGenVec, Inc. · 1999
- Packaging systems for human recombinant adenovirus to be used in gene therapy178US 6,033,908 AIntrogene B.V. · 2000